![Will West](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Will West
Former positions of Will West
Companies | Position | Start | End |
---|---|---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20/11/2009 | 18/01/2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Training of Will West
London Business School | Masters Business Admin |
Statistics
International
United Kingdom | 3 |
United States | 2 |
Operational
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sectoral
Commercial Services | 2 |
Miscellaneous | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
Procter & Gamble Health & Beauty Care | Miscellaneous |
- Stock Market
- Insiders
- Will West
- Experience